International Top Pharmaceutical Awards

The Innovative Research Award recognizes outstanding researchers, scientists, academicians, and industry professionals who have demonstrated exceptional innovation and groundbreaking contributions in pharmaceutical sciences. This prestigious honor celebrates pioneering research that advances drug discovery, pharmaceutical development, biotechnology, precision medicine, clinical therapeutics, and healthcare innovation. The award aims to acknowledge visionary individuals whose research has the potential to transform patient care, improve healthcare outcomes, and drive the future of the global pharmaceutical industry.    Visit Our Website : toppharmaceutical.org | Nomination link : https://w-i.me/smph Contact us : contact@toppharmaceutical.org #TopPharmaceutical #WorldResearchAwards #ResearchAwards #ResearchExcellence #GlobalRecognition#InnovativeResearchAward #TopPharmaceuticalAwards #PharmaceuticalResearch #DrugDiscovery #PharmaInnovation

  The DNA foundation model Evo 2 has been published in the journal  Nature . Trained on the DNA of over 100,000 species across the entire tree of life, Evo 2 can identify patterns in gene sequences across disparate organisms that experimental researchers would need years to uncover. The machine learning model can accurately identify disease-causing mutations in human genes and is capable of designing new genomes that are as long as the genomes of simple bacteria. Evo 2 was developed by scientists from Arc Institute and NVIDIA, convening collaborators across Stanford University, UC Berkeley, and UC San Francisco. The model's code is publicly accessible from Arc's GitHub, and is also integrated into the NVIDIA BioNeMo framework, as part of a collaboration between Arc Institute and NVIDIA to accelerate scientific research. Arc Institute also worked with AI research lab Goodfire to develop a mechanistic interpretability visualizer that uncovers the key biologic...

   One stem cell generates 14 million tumor-killing natural killer (NK) cells in major cancer breakthrough. Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By engineering early-stage stem cells from cord blood—rather than trying to modify mature natural killer (NK) cells—they created a streamlined process that generates enormous numbers of highly potent NK cells, including CAR-equipped versions designed to hunt specific cancers. NK cells play a critical role in the body’s early defense against viruses and cancer, along with other immune functions. Because of their natural ability to detect and destroy abnormal cells, they are an attractive tool for cancer treatment. In chimeric antigen receptor (CAR)-NK therapy, scientists equip NK cells with a lab-designed receptor (a CAR) so they can recognize a specific marker on cancer cells and attack them more precisely. Traditional CAR-NK approaches usually depend on...

  Viral infectious diseases have caused millions of deaths worldwide. Antiviral agents are critical for controlling these infections; however, an open-access database dedicated specifically to antiviral agents remains unavailable. Here, we present AntiviralDB  an expert-curated resource that compiles both approved and experimental antiviral agents with laboratory-confirmed   in vitro   activity against a broad spectrum of human viruses. These include the human immunodeficiency virus, coronaviruses, hepatitis viruses, influenza virus, respiratory syncytial virus, herpes simplex virus, varicella-zoster virus, human cytomegalovirus, human papillomavirus, dengue virus, Zika virus, Ebola virus, mpox virus, norovirus, chikungunya virus, and 16 other common or life-threatening pathogens. Each antiviral agent in the database is annotated with key information, including its molecular target,   in vitro   antiviral activity (IC 50 , EC 50 , and CC 50   across sp...

  Scientists identify a key enzyme enabling cancer cells to rapidly rewire DNA, accelerating mutations, adaptation, and treatment resistance across tumors. Visit Our Website : toppharmaceutical.org Nomination link : https://toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee Contact us : contact@toppharmaceutical.org #Cancer #Enzyme #DNA #Mutation #Genomics #Oncology #Biology #Research #Science #Medicine #Tumor

  Three years ago, Portnoy cofounded a startup, Laguna Biotherapeutics, that worked with scientists in his University of California, Berkeley lab to eliminate the bacteria's ability to cause disease while retaining its ability to rev up production of a type of immune system cell associated with increased survival in cancer patients. These so-called  gamma delta T cells  are general-purpose killers of cancer cells or any cell infected by a pathogen—bacteria, virus, or fungus. Laguna Bio will soon ask the FDA for clearance to evaluate the therapy in children with leukemia who have received unmatched bone marrow transplants. Stanford University Medical Center doctors hope that the engineered Listeria will boost gamma delta T cells in pediatric patients and help them stave off graft-versus-host disease, fight potentially deadly infections that take advantage of a transplant patient's compromised immune system, and prevent the cancer from returning. Portnoy and his colleagues ...

  Alembic Pharmaceuticals Ltd  has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbidopa, Levodopa and Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg. Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson’s disease.  IPCA Laboratories  informed the exchanges that manufacturing facility at Tarapur (Maharashtra) has now received Establishment Inspection Report classifying the manufacturing facility as “Voluntary Action Indicated (VAI) and that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP) from the US FDA. Earlier, it  Zydus Lifescience , a leading, discovery-based, global pharmaceutical company has announced that the USFDA has granted Orphan Drug Des...

  It's easy to feel powerless against cancer, but a new study has identified several ways that we can reduce the odds of it occurring. According to new analysis from the World Health Organization (WHO), more than a third of all cancer cases globally are preventable. Lung, stomach, and cervical cancers make up nearly half of those cases. This means that millions of deadly cancers every year could be prevented through medical intervention, behavior changes, reducing occupational risks, or tackling environmental pollutants. "Addressing these preventable causes represents one of the most powerful opportunities to reduce the global cancer burden," says Isabelle Soerjomataram, medical epidemiologist at WHO and senior author of the analysis. Visit Our Website : toppharmaceutical.org  Nomination link : https://toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee                  ...

  In the realm of organ transplantation, the integration of pharmacogenomics into clinical practice has emerged as a transformative approach that holds the potential to significantly enhance patient outcomes. The recent literature, particularly a review by researchers K.D. Belfield, E.A. Cohen, and G. Girone, sheds light on the profound implications of pharmacogenomics in transplantation. This exciting field explores how an individual’s genetic makeup can influence their response to medications, thereby revolutionizing personalized medicine in organ transplant recipients. At the heart of pharmacogenomics is the interaction between genetics and drug metabolism. Each patient possesses a unique genetic profile that impacts how their body processes medications. In the context of transplantation, this means that the standard immunosuppressive therapies often prescribed may not be equally effective for every individual. By understanding these genetic variances, clinicians can tailor medi...

  Every time we think we’re close to fully understanding the human body, something fresh and unexpected shows up. Recently, a team of researchers stumbled upon strange entities, or obelisks, living inside of human bodies that had escaped notice until now. These new visitors appear smaller than the viruses most people learn about in basic biology classes. Rather than behaving like familiar microbes, they introduce themselves as something different. Their discovery came about when researchers began analyzing massive genetic libraries, searching for patterns that did not match any known organisms. Visit Our Website : toppharmaceutical.org  Nomination link : https://toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee                                                              ...

  Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic disease. Scientists found their immune systems retained long-lasting memory cells primed to recognize cancer. By enhancing a key immune signal called CD27, researchers dramatically improved tumor elimination in lab studies. The findings suggest cancer vaccines may have been missing a crucial ingredient all along. A decades-old cancer vaccine left patients’ immune systems fighting strong—and scientists may have finally figured out why. Credit: Shutterstock More than two decades ago, a small group of women with advanced breast cancer took part in a clinical trial that tested an experimental vaccine. All these years later, every one of them is still alive. Researchers say survival over such a long period is extremely uncommon for people with metastatic breast cancer, which is why the case drew renewed scientific attention. Researchers at Duke Health took a closer lo...

  Researchers unveil a first-in-class inhibitor that shuts down a key epigenetic switch driving lung cancer growth. A research team by Professor Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU), in collaboration with researchers from the Shenzhen Bay Laboratory and Tsinghua University, has made a breakthrough in epigenetic drug discovery. The team has successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC complex, a critical cellular “switch operator” that activates tumour-promoting genes, opening a novel therapeutic avenue for non-small cell lung cancer (NSCLC). The findings were recently published in the top-tier journal  Nature Chemical Biology , and multiple international patent applications have been filed. Histone Modifications as Genetic Switches in Our Cells Inside human cells, DNA is wrapped around protein structures called histones to form chromatin. Chemical modifi...

  Chromosomal abnormalities that occur during cell division can affect the cell’s health, in some cases causing a normal cell to become cancerous. The role of these aberrations in the progression of cancer, and the baseline rate at which they occur, remain poorly understood. To investigate the origins of chromosomal instability, researchers from the European Molecular Biology Laboratory (EMBL) created an autonomous platform to examine the cellular context, mutation rates, and triggers leading to the spontaneous formation of chromosomal abnormalities. The researchers tested the platform on cell line models that mimicked the early stages in tumor evolution. This tool, assisted by  artificial intelligence  (AI), could provide valuable insight into the molecular origins of cancer, laying the groundwork for new approaches to genetic research and potential strategies for preventing cancer. “Chromosomal abnormalities are a main driver for particularly aggressive cancers, and the...

  The combination therapy demonstrated substantial clinical benefits in trial data, with patients receiving talazoparib plus enzalutamide experiencing extended survival and delayed disease progression. Overall survival reached 45.8 months versus 37 months for the single-agent treatment – representing an improvement of nearly 9 months. Additionally, progression-free survival showed even more dramatic gains, extending to 33.1 months compared with 19.5 months on enzalutamide alone – a benefit of more than 13 months. Clinical trials found that people taking talazoparib with enzalutamide lived significantly longer and had more time before their cancer got worse. Overall survival was 45.8 months compared with 37 months for those on enzalutamide alone – an increase of nearly nine months. The time people live without their cancer getting worse also increased: 33.1 months compared with 19.5 months – an increase of over a year. “For these men, having talazoparib appr...

Description: The AI revolution is transforming clinical research by accelerating drug development , enhancing patient recruitment, and enabling precise data analysis. With advanced algorithms, AI is redefining the way researchers approach challenges, ensuring faster, more accurate outcomes that pave the way for groundbreaking treatments. International Top Pharmaceutical Awards Website link : toppharmaceutical.org Nomination : toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee Contact us: contact@toppharmaceutical.org #sciencefather #researchawards #clinicalresearch #artificialintelligence #aitechnology #medicalinnovation #aiinmedicine #drugdevelopment #precisionmedicine #healthtech #clinicaltrials #medicaladvancement #aihealthcare #patientcare #healthinformatics #digitalhealth #aiforhealth #medtechinnovation #aialgorithms #aiapplications #researchinnovation #dataanalytics #aiimpact #aiinscience #pharmatech #medtech #advancedhealthcare #pharmainnovation, #dru...

The strategy involves delivering genetic information for two types of molecules: a light-sensitive protein known as CoChR that can produce positively charged currents, and a bioluminescence-emitting enzyme. Packed into an altered virus particle and delivered to cancer cells, the proteins are produced as their genes are expressed in mitochondria. A follow-up injection of a specific chemical turns on the enzyme’s light to activate CoChR, which leads to mitochondrial collapse. The other half of the battle is ensuring this therapy does not interfere with normal cells. Liu’s lab specializes in targeted anti-cancer therapy development. The foundation for the delivery system in this work is the well-characterized adeno-associated virus (AAV), a minimally infectious virus engineered to carry genes and promote their expression for therapeutic purposes. The team refined the system to enhance its cancer specificity by adding a promoter protein to drive up expression of the CoChR and biolumine...

New safety information for healthcare professionals Veoza (fezolinetant): new recommendations to minimise risk of liver injury The PRAC has agreed to a direct healthcare professional communication (DHPC) informing of the risk of drug-induced liver injury (DILI) with Veoza (fezolinetant) and has recommended monitoring of liver function before and during treatment. Veoza is a medicine used to treat moderate-to-severe vasomotor symptoms (also referred to as hot flushes or night sweats) associated with menopause. The committee considered a review of the potential risk of fezolinetant to cause drug-induced liver injury based on information from all available sources, including reports of suspected side effectsand studies published in the scientific literature. Severe elevations of the liver enzymes alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (>10x upper limit of normal) with concurrent elevations in bilirubin and/or alkaline phosphatase (ALP) have been reporte...